HK1090033A1 - Benzoazolypiperazine derivatives having vr1 antagonist activity - Google Patents
Benzoazolypiperazine derivatives having vr1 antagonist activityInfo
- Publication number
- HK1090033A1 HK1090033A1 HK06110337.5A HK06110337A HK1090033A1 HK 1090033 A1 HK1090033 A1 HK 1090033A1 HK 06110337 A HK06110337 A HK 06110337A HK 1090033 A1 HK1090033 A1 HK 1090033A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- benzoazolypiperazine
- derivatives
- antagonist activity
- antagonist
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43591702P | 2002-12-24 | 2002-12-24 | |
US45962603P | 2003-04-03 | 2003-04-03 | |
US47385603P | 2003-05-29 | 2003-05-29 | |
PCT/US2003/041100 WO2004058754A1 (en) | 2002-12-24 | 2003-12-22 | Benzoazolypiperazine derivatives having mglur1- and mglur5-antagonistic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1090033A1 true HK1090033A1 (en) | 2006-12-15 |
Family
ID=32686087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06110337.5A HK1090033A1 (en) | 2002-12-24 | 2006-09-18 | Benzoazolypiperazine derivatives having vr1 antagonist activity |
Country Status (26)
Country | Link |
---|---|
US (5) | US7582635B2 (ja) |
EP (1) | EP1583763B1 (ja) |
JP (4) | JP4680774B2 (ja) |
KR (1) | KR20050087867A (ja) |
CN (1) | CN100560584C (ja) |
AR (1) | AR043324A1 (ja) |
AT (1) | ATE390423T1 (ja) |
AU (1) | AU2003297506A1 (ja) |
BR (1) | BR0317757A (ja) |
CA (1) | CA2511509C (ja) |
CY (1) | CY1108155T1 (ja) |
DE (1) | DE60320033T2 (ja) |
DK (1) | DK1583763T3 (ja) |
EA (1) | EA200501022A1 (ja) |
ES (1) | ES2303609T3 (ja) |
HK (1) | HK1090033A1 (ja) |
HR (1) | HRP20050666B1 (ja) |
IL (1) | IL169378A0 (ja) |
MX (1) | MXPA05006869A (ja) |
NO (1) | NO20053582L (ja) |
NZ (1) | NZ541415A (ja) |
PL (1) | PL377514A1 (ja) |
PT (1) | PT1583763E (ja) |
RS (1) | RS20050498A (ja) |
SI (1) | SI1583763T1 (ja) |
WO (1) | WO2004058754A1 (ja) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4077320B2 (ja) | 2001-01-29 | 2008-04-16 | 塩野義製薬株式会社 | 5−メチル−1−フェニル−2−(1h)−ピリドンを有効成分として含有する医薬製剤 |
TWI350285B (en) * | 2002-03-13 | 2011-10-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
WO2004035549A1 (en) * | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
US7582635B2 (en) * | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
EP1867644B1 (en) * | 2003-07-24 | 2009-05-20 | Euro-Celtique S.A. | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
DE602004017316D1 (de) * | 2003-07-24 | 2008-12-04 | Euro Celtique Sa | Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen |
US7754711B2 (en) * | 2003-07-30 | 2010-07-13 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
ES2374017T3 (es) | 2003-08-01 | 2012-02-13 | Euro-Celtique S.A. | Agentes terapéuticos útiles para el tratamiento del dolor. |
US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
SE0303418D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 1 |
SE0303419D0 (sv) * | 2003-12-17 | 2003-12-17 | Astrazeneca Ab | New use 11 |
SE0303489D0 (sv) * | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use VII |
SE0303488D0 (sv) * | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use 1X |
GB0510141D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
EP1752143A1 (en) * | 2005-08-08 | 2007-02-14 | NewThera | Novel uses for drugs targeting glutamine synthetase |
PE20080707A1 (es) * | 2006-06-01 | 2008-05-22 | Wyeth Corp | Derivados de benzoxazol y benzotiazol como ligandos de 5-hidroxitriptamina-6 |
TW200814968A (en) * | 2006-06-07 | 2008-04-01 | Combinatorx Inc | Methods and compositions for the treatment of diseases or conditions associated with increased C-reactive protein levels |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
WO2008057300A2 (en) * | 2006-10-27 | 2008-05-15 | Redpoint Bio Corporation | Trpvi antagonists and uses thereof |
MX2009011601A (es) * | 2007-04-27 | 2009-11-10 | Purdue Pharma Lp | Agentes terapeuticos utiles para tratar el dolor. |
AU2011226773C1 (en) * | 2007-04-27 | 2012-07-26 | Purdue Pharma L.P. | TRPV1 antagonists and uses thereof |
MY148657A (en) * | 2007-04-27 | 2013-05-15 | Purdue Pharma Lp | Trpv1 antagonists and uses thereof |
US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
KR20210107137A (ko) | 2008-04-21 | 2021-08-31 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
WO2010011605A2 (en) | 2008-07-21 | 2010-01-28 | Otonomy, Inc. | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders |
US8703962B2 (en) * | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
EP2585446A4 (en) | 2010-06-22 | 2013-12-25 | Shionogi & Co | COMPOUNDS WITH ANTAGONISTIC EFFECT AGAINST TRPV1 AND THEIR USE |
US9474454B2 (en) * | 2010-10-20 | 2016-10-25 | Advanced Mri Technologies Llc | MRI using faster multiplexed echo planar imaging (EPI) pulse sequences |
EP2662016A4 (en) | 2011-01-28 | 2017-04-12 | Olympus Corporation | Capsule endoscope system |
US9918980B2 (en) | 2011-04-29 | 2018-03-20 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
US10736889B2 (en) | 2011-04-29 | 2020-08-11 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
PT2701707T (pt) * | 2011-04-29 | 2020-11-09 | Univ Rutgers | Método de tratamento de discinésia |
WO2012158844A1 (en) | 2011-05-17 | 2012-11-22 | Shionogi & Co., Ltd. | Heterocyclic compounds |
MY185061A (en) | 2011-06-22 | 2021-04-30 | Shionogi & Co | Trpv1 antagonists including dihydroxy substituent and uses thereof |
WO2013021276A1 (en) | 2011-08-10 | 2013-02-14 | Purdue Pharma L.P. | Trpv1 antagonists including dihydroxy substituent and uses thereof |
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8716277B2 (en) | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
US9637775B2 (en) | 2012-02-13 | 2017-05-02 | Neumodx Molecular, Inc. | System and method for processing biological samples |
CN104271765B (zh) | 2012-02-13 | 2017-04-26 | 纽莫德克斯莫勒库拉尔公司 | 用于处理和检测核酸的系统和方法 |
US11648561B2 (en) | 2012-02-13 | 2023-05-16 | Neumodx Molecular, Inc. | System and method for processing and detecting nucleic acids |
US11485968B2 (en) | 2012-02-13 | 2022-11-01 | Neumodx Molecular, Inc. | Microfluidic cartridge for processing and detecting nucleic acids |
US8924211B2 (en) * | 2012-07-09 | 2014-12-30 | Nuance Communications, Inc. | Detecting potential significant errors in speech recognition results |
US9064492B2 (en) | 2012-07-09 | 2015-06-23 | Nuance Communications, Inc. | Detecting potential significant errors in speech recognition results |
US20140120544A1 (en) | 2012-10-25 | 2014-05-01 | Neumodx Molecular, Inc. | Method and materials for isolation of nucleic acid materials |
US9054800B2 (en) | 2013-09-11 | 2015-06-09 | Symbol Technologies, Llc | Staging a mobile device with visible light communication |
RU2642821C2 (ru) | 2013-12-02 | 2018-01-29 | Мастеркард Интернэшнл Инкорпорейтед | Способ и система для защищенной передачи сообщений сервиса удаленных уведомлений в мобильные устройства без защищенных элементов |
US10275767B2 (en) | 2014-10-21 | 2019-04-30 | Mastercard International Incorporated | Method and system for generating cryptograms for validation in a webservice environment |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
CN109561680B (zh) * | 2016-06-23 | 2021-07-13 | 圣朱德儿童研究医院 | 泛酸激酶的小分子调节剂 |
US10821185B2 (en) | 2016-06-29 | 2020-11-03 | Otonomy Inc. | Triglyceride otic formulations and uses thereof |
CN106918697B (zh) * | 2017-02-15 | 2018-07-31 | 中国医学科学院北京协和医院 | 一种预测ra药物疗效的诊断标志物及其应用 |
CA3058216C (en) | 2017-03-30 | 2023-08-15 | Xw Laboratories Inc. | Bicyclic heteroaryl derivatives and preparation and uses thereof |
CA3086711A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
CA3086671A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital, Inc. | Small molecule modulators of pantothenate kinases |
JPWO2021070957A1 (ja) * | 2019-10-09 | 2021-04-15 | ||
CN111887828B (zh) * | 2020-07-08 | 2021-05-07 | 中南大学湘雅医院 | 围术期患者非接触式生理信息监测装置、计算机设备和存储介质 |
CN112986452B (zh) * | 2021-05-10 | 2021-08-13 | 湖南慧泽生物医药科技有限公司 | 测定人血浆中坦度螺酮浓度的方法 |
CN113390941B (zh) * | 2021-06-08 | 2022-07-01 | 浙江工业大学 | 一种基于离子液体涂层的flm-eks-cze在线富集测定有机酸含量的方法 |
CN114394415B (zh) * | 2021-12-28 | 2023-12-12 | 赤壁市万皇智能设备有限公司 | 一种基于agv自动搬运系统的fpc自动化生产线 |
DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
CN115936265B (zh) * | 2023-02-24 | 2023-06-16 | 华东交通大学 | 考虑电氢耦合的电氢能源系统鲁棒规划方法 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
US5198459A (en) | 1987-07-11 | 1993-03-30 | Sandoz Ltd. | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
US6204284B1 (en) | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5232934A (en) | 1992-07-17 | 1993-08-03 | Warner-Lambert Co. | Method for the treatment of psychomotor stimulant addiction |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
CN1144529A (zh) | 1994-03-14 | 1997-03-05 | 诺沃挪第克公司 | 杂环化合物,它们的制备和应用 |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5556837A (en) | 1994-08-01 | 1996-09-17 | Regeneron Pharmaceuticals Inc. | Methods for treating addictive disorders |
DE19514313A1 (de) | 1994-08-03 | 1996-02-08 | Bayer Ag | Benzoxazolyl- und Benzothiazolyloxazolidinone |
US5762925A (en) | 1994-11-03 | 1998-06-09 | Sagen; Jacqueline | Preventing opiate tolerance by cellular implantation |
AU6111796A (en) | 1995-06-12 | 1997-01-09 | G.D. Searle & Co. | Compositions comprising a cyclooxygenase-2 inhibitor and a 5 -lipoxygenase inhibitor |
US5798360A (en) | 1996-08-01 | 1998-08-25 | Isis Pharmaceuticals, Inc. | N-(aminoalkyl)- and/or N-(amidoalkyl)- dinitrogen heterocyclic compositions |
WO1999009140A1 (en) | 1997-08-20 | 1999-02-25 | The Regents Of The University Of California | Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof |
NZ505207A (en) | 1997-11-21 | 2003-10-31 | Nps Pharma Inc | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
JPH11199573A (ja) | 1998-01-07 | 1999-07-27 | Yamanouchi Pharmaceut Co Ltd | 5ht3受容体作動薬及び新規ベンゾチアゾール誘導体 |
JP4676613B2 (ja) | 1998-01-27 | 2011-04-27 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | 置換オキソアザヘテロシクリルXa因子阻害剤 |
EP0943683A1 (en) | 1998-03-10 | 1999-09-22 | Smithkline Beecham Plc | Human vanilloid receptor homologue Vanilrep1 |
GB9907097D0 (en) | 1999-03-26 | 1999-05-19 | Novartis Ag | Organic compounds |
AU768720B2 (en) | 1999-04-01 | 2004-01-08 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
US6109269A (en) | 1999-04-30 | 2000-08-29 | Medtronic, Inc. | Method of treating addiction by brain infusion |
US6340681B1 (en) * | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
DE19934799B4 (de) | 1999-07-28 | 2008-01-24 | Az Electronic Materials (Germany) Gmbh | Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten |
MXPA02001340A (es) | 1999-08-05 | 2004-07-16 | Prescient Neuropharma Inc | Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos. |
CA2398754A1 (en) | 2000-02-07 | 2001-08-09 | Abbott Gmbh & Co. Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
CA2415606A1 (en) | 2000-07-20 | 2002-01-31 | Neurogen Corporation | Capsaicin receptor ligands |
JP2003192673A (ja) | 2001-12-27 | 2003-07-09 | Bayer Ag | ピペラジンカルボキシアミド誘導体 |
PT1472225E (pt) | 2002-02-01 | 2010-07-30 | Euro Celtique Sa | 2-piperazina-piridinas uteis para tratar a dor |
US6974818B2 (en) | 2002-03-01 | 2005-12-13 | Euro-Celtique S.A. | 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain |
EP1556354B1 (en) | 2002-06-28 | 2008-01-23 | Euro-Celtique S.A. | Therapeutic piperazine derivates useful for treating pain |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
WO2004035549A1 (en) * | 2002-10-17 | 2004-04-29 | Amgen Inc. | Benzimidazole derivatives and their use as vanilloid receptor ligands |
US7582635B2 (en) * | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
AU2004276252B2 (en) | 2003-09-22 | 2007-11-22 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
DK1664041T3 (da) | 2003-09-22 | 2008-10-27 | Euro Celtique Sa | Phenylcarboxamidforbindelser, der er egnede til behandling af smerter |
BRPI0417902A (pt) * | 2003-12-30 | 2007-04-10 | Euro Celtique Sa | piperazinas úteis no tratamento da dor |
-
2003
- 2003-12-19 US US10/739,190 patent/US7582635B2/en not_active Expired - Fee Related
- 2003-12-22 PT PT03814351T patent/PT1583763E/pt unknown
- 2003-12-22 BR BR0317757-2A patent/BR0317757A/pt not_active IP Right Cessation
- 2003-12-22 RS YUP-2005/0498A patent/RS20050498A/sr unknown
- 2003-12-22 SI SI200331239T patent/SI1583763T1/sl unknown
- 2003-12-22 DE DE60320033T patent/DE60320033T2/de not_active Expired - Lifetime
- 2003-12-22 DK DK03814351T patent/DK1583763T3/da active
- 2003-12-22 EP EP03814351A patent/EP1583763B1/en not_active Expired - Lifetime
- 2003-12-22 EA EA200501022A patent/EA200501022A1/ru unknown
- 2003-12-22 CA CA2511509A patent/CA2511509C/en not_active Expired - Fee Related
- 2003-12-22 WO PCT/US2003/041100 patent/WO2004058754A1/en active Application Filing
- 2003-12-22 KR KR1020057012074A patent/KR20050087867A/ko not_active Application Discontinuation
- 2003-12-22 MX MXPA05006869A patent/MXPA05006869A/es active IP Right Grant
- 2003-12-22 PL PL377514A patent/PL377514A1/pl not_active Application Discontinuation
- 2003-12-22 ES ES03814351T patent/ES2303609T3/es not_active Expired - Lifetime
- 2003-12-22 NZ NZ541415A patent/NZ541415A/en not_active IP Right Cessation
- 2003-12-22 CN CNB200380109900XA patent/CN100560584C/zh not_active Expired - Fee Related
- 2003-12-22 JP JP2005510054A patent/JP4680774B2/ja not_active Expired - Fee Related
- 2003-12-22 AU AU2003297506A patent/AU2003297506A1/en not_active Abandoned
- 2003-12-22 AT AT03814351T patent/ATE390423T1/de active
- 2003-12-23 AR ARP030104839A patent/AR043324A1/es unknown
-
2005
- 2005-06-23 IL IL169378A patent/IL169378A0/en unknown
- 2005-07-22 NO NO20053582A patent/NO20053582L/no not_active Application Discontinuation
- 2005-07-22 HR HR20050666A patent/HRP20050666B1/xx not_active IP Right Cessation
-
2006
- 2006-09-18 HK HK06110337.5A patent/HK1090033A1/xx not_active IP Right Cessation
-
2008
- 2008-06-24 CY CY20081100660T patent/CY1108155T1/el unknown
-
2009
- 2009-07-08 US US12/499,480 patent/US8008300B2/en not_active Expired - Lifetime
-
2010
- 2010-09-03 JP JP2010197627A patent/JP5437954B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-08 US US13/205,323 patent/US8536177B2/en not_active Expired - Fee Related
- 2011-08-18 US US13/212,941 patent/US8604037B2/en active Active
-
2013
- 2013-05-02 JP JP2013096806A patent/JP5908861B2/ja not_active Expired - Lifetime
- 2013-12-06 US US14/099,738 patent/US9434721B2/en not_active Expired - Lifetime
-
2014
- 2014-12-10 JP JP2014249728A patent/JP6005712B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1090033A1 (en) | Benzoazolypiperazine derivatives having vr1 antagonist activity | |
IL174990A0 (en) | Compounds having crth2 antagonist activity | |
TWI319387B (en) | Benzamide derivatives | |
AP1850A (en) | Spiroindolineplperidine derivatives | |
EG24050A (en) | Heterocylocarboxamide derivatives | |
HK1077068A1 (en) | Azolidinone-vinyl fused-benzene derivatives | |
IL166121A0 (en) | Indole-3-sulphur derivatives | |
EP1522540A4 (en) | AZAARENE DERIVATIVES | |
IL165841A0 (en) | Mchir antagonists | |
PL376475A1 (en) | N-substituted-2-oxodihydropyridine derivatives | |
HUP0402171A3 (en) | Pyrazolopyrimidinone derivatives having pde7-inhibitory activity | |
IL166426A0 (en) | N-biarylmethyl aminocycloalkanecarboxamide derivatives | |
GB0224292D0 (en) | Construction unit | |
AU2003222659A8 (en) | 23-o-substituted 5-o-mycaminosyltylonide derivatives | |
AU2003290818A8 (en) | Topoisomerase-targeting agents | |
EP1531854A4 (en) | O-DERIVATED NOCATHIACIN DERIVATIVES | |
GB0213488D0 (en) | 2-Naphthamide derivatives | |
AU2003243397A8 (en) | Homo-camptothecin derivatives | |
TW532412U (en) | Improved structure for construction forms | |
TW519000U (en) | Structure improvement for sprinkler | |
HUP0200109D0 (en) | Compounds having pharmaceutical activity | |
HUP0204362D0 (en) | Compounds having pharmaceutical activity | |
GB0204798D0 (en) | Cycostatic agents | |
GB0228610D0 (en) | Benzamide derivatives | |
GB0207863D0 (en) | Benzamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191223 |